Navigation Links
Bio-Matrix Scientific Group CEO Tells Wall Street Transcript That 'Positive Cash Flow' Is Possible in '09; New Stem Cell Banking Facility Is Growth Vehicle Over the Next Two Years, Says CEO in Exclusive News Interview
Date:3/25/2009

SAN DIEGO, March 25 /PRNewswire-FirstCall/ -- David Koos, Chairman and CEO of San Diego-based Bio-Matrix Scientific Group Inc. (OTC Bulletin Board: BMSN), told the editors of The Wall Street Transcript, a New York City financial news weekly, that there is an excellent possibility that the company "would have positive cash flow" in '09 because of new business alliances and contracts "with companies engaged either in cryogenic banking, stem cell research, or cell culturing."

BMSN recently entered into a Human Cell Specimen Cryogenic Storage contract with NeoCells, Inc. and AdultCells, Inc. with a focus on the full spectrum of adult stem cells. BMSN was recently featured as "Stock of The Month" in the KonLin Letter (www.konlin.com), a New York-based investment newsletter, as well as in the WallStreetCorner.com investment newsletter (www.wallstreetcorner.com). The TWST news interview was published in the March 23rd issue.

According to Koos, Bio-Matrix's cGMP compliant 15,000 square foot cryogenic stem cell banking facility is highly secured and technologically advanced and is now gaining the respect of stem cell companies across the nation. "Our business model initially focuses on cord blood and peripheral blood," said Koos. "We have an interest in other stem cells as we roll out our model. Our first step is to develop our revenue stream from cord blood because existing specimens are available. Over the next 18 months, we're looking at enhancing the cord blood specimen and peripheral blood banking strategies."

Koos described Bio-Matrix as a "conservative player in the stem cell industry." The CEO pointed out that the company is developing a unique niche within the stem cell industry as a place for stem cell companies to store blood specimens for research and treatment of diseases. "We are the shipping container, we are the foundation, we're the driveway. We're not rolling the dice on getting FDA approval on some therapy that may take ten years to develop," said Koos in the TWST news interview. "We plan to fill a key niche in the marketplace now."

About Bio-Matrix Scientific Group

Bio-Matrix Scientific Group Inc. (OTCBB: BMSN) is a biotech research and development company that commercializes medical devices and monitoring systems for the growing worldwide stem cell research market. Its new 15,000 square foot facility houses two secure cryogenic stem cell banks, three research laboratories, aseptic cellular/tissue class 10,000/100 processing lab, hematology, microbiology and flow cytometry laboratories.

Disclaimer

This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.


'/>"/>
SOURCE Bio-Matrix Scientific Group Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Bio-Matrix Scientific Group Announces New Hires to Management Team
2. Bio-Matrix Scientific Group Featured as Stock Pick in Oakleys Column on WallStreetCorner.com
3. Bio-Matrix Scientific Group, Inc. Highlighted in LifeSciencesWorld.com Special Report; Stem Cell Market Projected to Exceed $8 Billion Worldwide by 2016
4. Bio-Matrix Scientific Group, Inc. Gets Updated Stock Recommendation By KonLin Investment Letter
5. Boston Scientific to Explore Sale of Cardiac Surgery and Vascular Surgery Businesses
6. Thermo Fisher Scientific Executive Officers Adopting SEC Rule 10b5-1 Trading Programs
7. Kewaunee Scientific Announces First Quarter Results and Quarterly Dividend
8. Ralf Rosskamp, M.D. Joins Biodels Scientific Advisory Board
9. Boston Scientific Amends Credit Facility and Prepays $1 Billion on Loan
10. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
11. Thermo Fisher Scientific to Present at Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased ... of over 5.5 million people each year. Especially those living in larger cities are ... - based in one of the most pollution-affected countries globally - decided to take ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and ... of osteosarcoma. SBT-100 is able to cross the cell membrane and bind intracellular ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give ... Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital Los Angeles ...
(Date:10/10/2017)... California (PRWEB) , ... October 10, 2017 , ... Dr. ... speaking at his local San Diego Rotary Club. The event entitled ... Diego, CA and had 300+ attendees. Dr. Harman, DVM, MPVM was joined by ...
Breaking Biology Technology:
(Date:5/16/2017)... May 16, 2017  Veratad Technologies, LLC ( www.veratad.com ... age and identity verification solutions, announced today they will ... 2017, May 15 thru May 17, 2017, in ... International Trade Center. Identity impacts the ... in today,s quickly evolving digital world, defining identity is ...
(Date:4/18/2017)... SUNNYVALE, Calif. , April 18, 2017  Socionext Inc., a ... prototype of a media edge server, the M820, which features the ... face recognition software provided by Tera Probe, Inc., will be showcased ... and at the NAB show at the Las Vegas ... ...
(Date:4/11/2017)... -- Research and Markets has announced the addition of ... offering. ... market to grow at a CAGR of 30.37% during the period ... has been prepared based on an in-depth market analysis with inputs ... growth prospects over the coming years. The report also includes a ...
Breaking Biology News(10 mins):